Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors.

ABSTRACT: Combination administration is becoming a popular strategy in current cancer immunotherapy to enhance tumor response to ICIs. Recently, a peptide drug, a protein-protein interaction inhibitor (PPI), that disrupts the β-catenin/Bcl9 interaction in the tumoral Wnt/β-catenin pathway has become a promising candidate drug for immune enhancement and tumor growth inhibition. However, the peptide usually suffers from poor cell membrane permeability and proteolytic degradation, limiting its adequate accumulation in tumors and ultimately leading to side effects. Herein, a gadolinium-gold-based core/shell nanostructure drug delivery system was established, where Bcl9 was incorporated into a gadolinium-gold core-shell nanostructure and formed GdOFBAu via mercaptogenic self-assembly. After construction,

SUBMITTER: You W 

PROVIDER: S-EPMC9228893 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature